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The ultimate goal in antibiotic treatment of acute otitis media (AOM) is eradication of the pathogens from the middle 
ear fluid (MEF). To test the ability of an antibiotic to achieve this goal, the best available method is to obtain MEF by 
aspiration before initiating antibiotics and to  repeat this procedure during treatment, a method which was termed the 
‘in vivo sensitivity test‘. This advantageous method is difficult t o  perform and thus only a few groups were able to  
conduct such large-scale studies. The available information is discussed in the present manuscript, as well as some 
preliminary results suggesting that oral p-lactam antibiotics may not be the ideal drugs to date, due to the emergence 
of resistant pneumococci. 
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BACKGROUND A N D  RATIONALE 
Acute otitis media (AOM) is the most coninion cause 
of antibiotic administration to infants and young child- 
ren. Its bacteriology is well known and comprises three 
main pathogens: Streptococcus yrieurnoniiie (Pnc), non- 
typeable Hrlenzophilus influerime (NTHi) and, to a lesser 
extent, Moruxeh catavrlialis (MC). Despite the high 
prevalence of the disease and the narrow spectrum of 
pathogens, many controversies still exist regarding the 
nianagement of AOM. Controversial issues, which are 
beyond the scope of the present article, include the 
need for antibiotic treatment, duration of treatment, 
the role of tynipanocentesis as a therapeutic measure, 
and the need for adjuvant treatment such as steroidal 
and non-steroidal anti-inflammatory drugs. 
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In the present article, the evaluation of short-term 
effects of antibiotics will be discussed, with emphasis on 
the microbiological efficacy of various antibiotics used 
in the treatment of AOM in early childhood. 
By definition, the role of antibiotics in AOM is to 
eradicate the causative organisnis from the middle ear. 
Thus, before any clinical testing it is required that the 
agent is evaluated in vitro and/or in animal models for 
its activity against the coninion bacterial pathogens of 
AOM [l]. However, the ultiniate challenge is eradication 
of the pathogens in humans. Strict results for such a 
challenge can be obtained only by performing randon- 
ized comparative studies in patients with AOM from 
whom an initial middle ear fluid (MEF) was obtained 
immediately before antibiotic administration and a 
second one during the course of treatment. Thic method 
has been strongly advocated by Howie and I’louscard 
and was termed by them ‘in vivo sensitivity test’ [2]. 
The advantage of in vivo susceptibility testing is 
that, with relatively few subjects, it can discriminate 
between drugs and predict clinical efficacy [3-81. 
The disadvantages of the method are that: (1) it requires 
a repeat tympanocentesis, often when the child is 
already improved, which may be considered by some 
authorities as unethical; and (2) only a few centers are 
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able to conduct such a study due to its complexity 
and the requirement of close collaboration between 
pediatricians, otolaryngologists and bacteriologists. 
Comparative studies requiring only one initial tap 
in their design and looking at clinical efficacy (using 
a second tap only when clinical failure is observed) 
are the next alternative. However, as pointed out by 
Marchant et a1 [8], a much larger sample size will be 
needed. For example, a difference of bacteriologic 
efficacy of 20% will be associated with a difference of 
only 6% in clinical outcome, thus increasing the need 
for the group size to be recruited from 301 patients 
with the two-tap method to 2464 patients with the 
one-tap method [8]. This kind of figure can never be 
studied with the demand of a scrutinized design that 
involves ‘good clinical practice studies’. Thus, designs 
denlanding both an initial culture of MEF and a second 
one during treatment are not only the best, but also 
the most ethical, enabling us to reach clinically useful 
conclusions. This approach is even further supple- 
mented if a third tap is performed when clinical relapse 
is observed. 
RESULTS OF VARIOUS COMPARATIVE STUDIES 
USING ‘IN VlVO SUSCEPTIBILITY TESTING’ 
There is no ethical justification to perform comparative 
studies involving a placebo arm to date. Thus, we are 
bound to use previous data to estimate natural outcome 
of AOM. Howie described the natural course of 11 6 
children treated with placebo from whom a second 
culture was obtained during days 2-6 of treatment and 
found a persistence of 13 of 25 (52%) cases when the 
initial culture was positive for NTHi, 48 of 57 (84?4) 
cases with initial culture positive for Pnc and 13 of 21 
(62%) patients with initial culture positive for i2i[ovuxellu 
cutavrhulis (MC) [4]. Rates of eradication of Pnc, NTHi 
and M C  by various antibiotics in the few studies which 
used in vivo susceptibility testing are presented in 
Tables 1 to 3. All of these studies were performed by 
only three groups: from Galveston, TX;  Harrisburg, 
PA; and Cleveland, O H .  The paucity of researcher5 
performing ‘two-tap studies’ is an indication of the 
difficulties in performing such studies. However, as can 
be clearly seen from the tables, the information gained 
from such studies is enormous, although it is not 
complete. 
Table 1 Persistence rate of non-typeable Haemphilux irzzuenzae in AOM cultured at enrolment and on days 2-7 during 
treatment 
p-lactamase (+) P-lactamase (-) 
No. No. No. NO. No. No. 
Drug Ref. Day of tap tested positive (94) tested positive (“A) tested positive (96) 
Placebo 
Cyclacillin 
Ampicillin 
Amoxicillin 
Amoxicillin-clavulanate 
Cefaclor 
Cefixime 
Cefprozil 
Cefuroxiine axetil 
Cefpodoxinie 
Ceftriaxone 
Trimethoprin- 
sulfamethoxazole 
Triple sulfonaniides 
Erythromycin- 
triple sulfonamides 
Erythromycin 
Clarythroniycin 
4 
13 
4 
10 
13 
11 
7 
6 
12 
10 
5 
6 
9 
11 
7 
9 
9 
9 
14 
5 
4 
4 
4 
9 
2-6 
2-3 
2-6 
3 
2-3 
3-6 
3-5 
3-6 
3-6 
3 
3-6 
3-6 
2-7 
3-6 
3-5 
2-7 
2-7 
2-7 
2-4 
3-6 
2-6 
2-6 
2-6 
2-7 
25 
18 
11 
14 
23 
21 
13 
15 
44 
20 
18 
14 
30 
21 
10 
14 
5 
22 
30 
14 
2 
21 
8 
15 
12 (52) 
0 
1 (9) 
3 (21) 
0 
5 (24) 
5 (38) 
1 (7) 
11 (25) 
3 (IS) 
8 (44) 
4 (29) 
12 (40) 
1 (5) 
8 (57) 
1 (20) 
1 (5) 
0 
0 
1 (7) 
1 (-) 
1 (5) 
6 (75) 
12 (XO) 
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Table 2 Persistence rate of Stveptococctrr pneurnoniae in 
AOM cultured at enrollment and on days 2-7 during 
treatment 
~~ ~~~ ~~ 
No. No. 
Drug Ref. I)ay of tap tested positive (“A) 
Placebo 4 2-6 57 48 (84) 
Cyclacillin 13 2-3 40 0 
Ampicillin 4 2-6 10 0 
Aiiioxicillin 10 3 37 4 (11) 
13 2-3 35 0 
11 3-6 18 1 (6) 
7 3-5 14 1 (7) 
Ainoxicillin- 
clavulanate 6 3-6 21 0 
12 3-6 54 1 ( 2 )  
Cefaclor 10 3 37 1 (3) 
5 3-6 20 4 (20) 
6 3-6 14 2 (14) 
9 2-7 17 9 (53) 
CXixiine 11 3-6 19 7 (37) 
7 3-5 16 4 (25) 
Cefprozil 9 2-7 13 1 (8) 
Cefuroxime axetil 9 2-7 11 0 
Cefpodoxiiiie 9 2-7 24 4 (17) 
Ceftriaxorie 14 2 4  24 0 
Trimethopriiii- 
wlfaniethoxazole 5 3-6 19 0 
Triple sulfonamides 4 2-6 13 3 (23) 
Erythromycin- 
triple sulfonamides 4 2-6 25 0 
Erythromycin 4 2-6 7 1 (14) 
Clarythromycin 9 2-7 12 0 
Limitations of the data presented in Tables 1 to 3 
include: (1) small number of patients in many studies; 
(2) lack of data on resistance patterns (i.e. p-lactamase 
production by NTHi  and MC; penicillin resistance in 
Pnc); (3) lack of uniformity in the timing for the second 
cultures (at days 2-7); and (4) variations with time: the 
11 studies in the tables were performed in a period 
which exceeds 20 years and thus some of the validity 
of comparison may be lost, since the prevalence of 
resistant organisms has dramatically changed during 
the last two decades. Despite these limitations, ini- 
portant information can be derived from these data. 
Some findings are conclusive and others are only 
suggestive, providing an incentive for further studies. 
For otitis caused by NTHi  (Table l ) ,  it can be 
clearly seen that drugs such as ceftriaxone and cefixime 
are superior to amoxicillin or cefaclor, or to macrolides 
such as erythromycin and clarythromycin. However, 
the ability to draw further conclusions regarding other 
drugs is limited due to small numbers or changing 
patterns of resistance. Thus, drugs which are shown to 
be effective in Table 1, such as erythromycin-sulfa or 
trimethoprin-sulfamethoxazole, may not be so today. 
Kegarding Pnc (Table 2), again, some drugs, such 
as amoxicillin, amoxicdin-clavulanate or the macro- 
lides, are clearly superior to others such as cefixime and 
cefaclor. However, here again the changing pattern 
of Pnc susceptibilities, with the high prevalence of 
Table 3 Persistence ratc of niloraxella cntarrhalis in AOM cultured at enrollment and on days 2-7 during treatment 
P-lactainase (+) p-lat-tamasc (-) 
No. NO. No. No. No. NO. 
I3rug Ref. Day of tap tested positive (“A) tested positive (“A) tested positive (5%) 
Placebo 4 2-6 21 13 (62) - - - 
C yclacilliii 13 2-3 5 1 (20) - - - - 
Amoxicillin 30 3 6 0 - - - 
13 2-3 4 0 - 
11 3-6 12 3 (25) - - - 
7 3-5 8 1 (13) 7 1 (14) 1 0 
Aiiioxicillin- 
clavulanate 6 3-6 7 0 4 0 3 0 
Cefaaclor 1 0 3 2 0 - - - 
- 
- 
- - - 
- 
12 3-6 30 2 (7) - - - - 
- 
3-6 8 0 - 5 - - - 
6 3-6 7 2 (29) 7 2 (29) 0 0 
7 3-5 7 1 (14) 1 0 6 1 (17) 
Cefixim e 1 1  3-6 15 2 (7) 
Cefprozil 9 2-7 4 1 (25) 
Cefuroxliiie axctil 9 2-7 3 0 - - - 
Cefpodoxinie 9 2-7 15 6 (40) 
Ceftriaxone 14 2 - 4  20 3 (15) - - - - 
Trimethoprim- 
sulfaniethoxazole 5 3-6 9 0 - - - 
- - - - 
- - - - 
- 
- - - - 
- 
Clarythroniycin 9 2-7 3 1 (20) - - - - 
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resistance to various commonly used oral drugs, makes 
it extremely difficult to judge effectiveness when extra- 
polating data from periods in which 1-esistance was not 
prevalent. 
With MC (Table 3) interpretations are even more 
difficult, since the presence of M C  in middle ear fluid 
is less common than NTHi or Pnc, thus resulting in 
smaller numbers. However the data are clear enough to 
demonstrate that p-lactamase-sensitive drugs such as 
amoxicillin or even cefaclor are inferior to P-lactamase- 
resistant drugs such as amoxicillin-clavulanate. 
Since the numbers in Tables 1 to 3 are small, and 
since one antibiotic may be superior to others for one 
organism but inferior for other organisms, the content 
of Tables 1 to 3 was grouped by antibiotic for selected 
antibiotics in Table 4. Despite the limitations men- 
tioned above, it is clear that only antibiotics active in 
vitro against both pneumococci and NTHi  will provide 
reasonable bacteriologic results in vivo. 
A prospective ongoing study has been taking place 
in our center since May 1994 to evaluate the efficacy 
of oral cephalosporins in AOM. Patients aged 6 months 
to 3 years are enrolled if they present with acute otitis 
media of less than 7 days' duration, if they did not 
receive any antibiotic drug in the 3 days preceding 
the enrollment and if they are able to receive oral 
drugs. Tympanocentesis is performed and all culture- 
negative patients are excluded from analysis. Patients 
are randomized to receive either one of two oral 
cephalosporins (cefaclor 40 mg/g/day divided into 
three doses versus cefuroxime axetil 30 mg/g/day 
divided into two doses) for 10 days. 
A second tympanocentesis is performed strictly on 
days 4 to 5 during treatment to avoid variation in results 
between early (days 2 to 3) and late (days 6 to 7 )  
cultures. The patients are followed regularly on day 1 
(enrollment), days 4 or 5 (second culture), day 10 (end 
of treatment), day 1 7 k 2  and day 42+7 (1 week and 
1 month post-therapy). In addition to the culture 
on days 4 or 5, a third culture is performed if clinical 
relapse occurs after days 4 to 5. So far, 142 culture- 
positive evaluable patients have been entered from 
whom 180 pathogens have been isolated: 93 (52%) 
were NTHi, 76 (42%) were Pnc, and 11 (6%) were 
others. 
Table 5 shows the eradication rate of pathogens 
in the two study groups and demonstrates the useful- 
ness of frequent cultures. O f  the 37 occasions where 
bacteriologic failure was observed on days 4 to 5, 
clinical impression of failure was noted in only 10 
(27%) patients. In contrast, in only 9 of 13 (69%) cases 
of clinical impression of failure, bacteriologic failure 
occurred. In other words, by using clinical impression 
as the sole tool, only a minority of those with failure 
was identified and some clinically identified failures will 
be culture-negative. Thus, clearly, obtaining culture on 
days 4 to 5 is a more sensitive tool to detect failures. 
In addition, if culture was performed when clinical 
deterioration during treatment or during the first week 
post-treatment was noted, the differences between 
the two cephalosporins became statistically significant. 
These findings clearly exemplify the usefulness of mul- 
tiple cultures in optimizing comparative studies. 
In the same study we tried to determine whether 
intermediately penicillimresistant pneumococci have 
any clinical significance when present in middle ear 
fluid in acute otitis media [15]. For this purpose, 
we enrolled 78 patients aged 6 months to 3 years 
with acute pneumococcal otitis media receiving either 
oral cefuroxime axetil (41 patients) or oral cefaclor (37 
patients). The middle ear fluid was cultured im- 
mediately before treatment and on days 4-5 during 
treatment. A third culture was obtained if clinical 
relapse was observed. The MIC to penicillin was 
determined by E-test [16]. Thirty-four (39%) of the 
70 isolates had an MIC of 0.1-1.0 pg/mL to peni- 
cillin (thus defined as intermediately resistant to 
penicillin). 
Table 4 Bacteriologic response to selected antibiotics grouped from Tables 1 to 3 
NTHi Pnc MC Total 
Placebo 13/25 (52) 48/57 (84) 12/21 (57) 73/103 (71) 
Ampicillin-amoxicillin 14/82 (17) 6/114 (5) 4/30 (13) 24/226 (11) 
Amoxicdlin-clavulanate 12/59 (20) 1/75 (1) 2/37 (5) 151171 (9) 
Cefaclor 27/82 (33) 16/88 (18) 2/17 (12) 451387 (24) 
15/90 (17) Cefixime 1/31 (3) 11 /37 (30) 3/22 (14) 
10/31 (32) Cefprozil 8/14 (57) 1/13 (8) 1/4 (25) 
Cefpodoxime 1/22 (5) 4/24 (17) 6/15 (40) 11/61 (18) 
Trimethoprimsulfamethoxazole 1/14 (7) 0/19 (0) 0/9 (0) 1/42 (2) 
13/32 (41) Clarythroniycin 12/15 (80) 0/12 (0) 1/5 (20) 
Ceftriaxone 0/30 (0) 0/24 (0) 3/20 (15) 3/74 (4) 
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Table 5 Failure ratc according to  evaluation method in 140 culture-positive patients with otitis media with 180 organisms 
(numbers in  parentheses represent percentage) 
Evaluation method* 
1 2 3 
Cefuroxime Cefuroxinie CephaloFporin 
Organism axetil Cefaclor axetil Cefaclor axetil Cephalosporin 
NTHi 0/45 (0) 5/48 (10) 8/45 (18) 14/48 (29) 8/45 (18)$ 20/48 (42)$ 
Pnc 3/39 (8) 3/37 (8) 5/39 (13) 6/37 (16) 6/39 (15) 8/37 (22) 
Others 0/5 (0) 316 (50) 1/5 (20) 3/h (50) 1 /5 (20) 316 (50) 
Total 3/89 (3)* 10/91 ( 1 l ) t  14/89 (16) 23/91 (25) 15/89 (17M 31/91 (34)i  
Evuluution Method 
(1) Clinical appearance of failure on days 4-5 
(2) Positive culture on days 4-5 
(3) Any of the following: (a) positive culture on days 4-5; 
(b) positive culture on days 6-10 associated with clinical failure 
(c) positive culture with the original organism on days 11-17 associated with clinicdl failure 
*Only 1/3 were culture-positive. 
tOnly 8/10 were culture-positive. 
$P<O.05 between cefuroxime axetil and cefaclor groups. 
Table 6 Effect of increased MIC to  penicillin on bacteriologic response in  acute pneuniococcal otitis media treated by two 
oral cephalosporins 
MIC to penicillin (pg/inL) P 
(Chi-square for linear 
4 . 1  0.1-0.25 (1.38-1.0 trend in proportion) 
Patients treated with 
cefuroxime axetil (n=41) 2/22 (9%) 1/13 (8%) 3/6 (50%) 0.082 
cefaclor (n=37) 1/25 (4%) 3/7 (43%) 4/5 (80%) < 0.001 
Total 3/47 (6%) 4/19 (2%) 7/11 (64%) < 0.001 
Paticnts treated with 
There were 14 (18%) cases of failure (positive 
culture on days 4-5-12; relapse with the same sero- 
type-2). Table 6 presents bacteriologic results and 
clearly shows that the presence of intermediary peni- 
cillin-resistant pneuniococci in the middle ear fluid was 
associated with impaired eradication with the two oral 
drugs. Table 6 also shows a clear trend of better clinical 
results with cefuroxime axetil (MICs,j-0.125 pg/mL; 
MICoo-1 .0 pg/mL) than with cefaclor (MICju-0.25; 
MIC90-4.0). Here again, by using a relatively small 
number of patients, we were able to show a significant 
rate of bacteriologic failure associated with an in- 
creasing MIC to penicillin. 
In conclusion, the ‘in vivo’ susceptibility testing 
represents the best method to test and compare the 
efficacy of antibiotic drugs in AOM. With the help of 
this method we and others were able to obtain signi- 
ficant results providing us with clues as to which drugs 
may be more appropriate in the treatment of otitis 
media in the late 1990s. However, more studies using 
similar methodology are still needed to complete our 
understanding. 
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